Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
To Be Held September 11, 2013, 6:00 p.m. Eastern Time
KANSAS CITY, Kan., Aug. 29, 2013 /PRNewswire/ -- Aratana Therapeutics (Nasdaq: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets (pet therapeutics), today announced that it will host a Pet Therapeutics Primer and Product Update Event, to be held September 11, 2013, at the Four Seasons Hotel in Boston.
The purpose of the event is to comprehensively lay out the pet therapeutics regulatory framework and to provide a detailed program-by-program update on Aratana's current pet therapeutic development programs.
Pet Therapeutics Primer & Product Update
Wednesday, September 11, 2013
6:00 – 7:30 p.m. (Eastern Time)
Parris Room; Four Seasons Hotel Boston
The event will be webcast live beginning with the company presentations at 6:30 p.m. Eastern Time, and will then be made available as an archive on the Aratana Therapeutics website at aratana.investorroom.com.
Dr. Steven St. Peter, President and Chief Executive Officer of Aratana Therapeutics, will provide a brief introduction to the Company and its pipeline of pet therapeutic product candidates. He also will discuss Aratana's licensing and partnership strategy for expanding its development pipeline.
Dr. Linda Rhodes, Aratana's Chief Scientific Officer, will provide an overview of the regulatory framework at the FDA's Center for Veterinary Medicine; specifically, the three concurrent regulatory work-streams: safety, efficacy and manufacturing. Dr. Rhodes also will discuss the mechanics of filing an administrative New Animal Drug Application (NADA) and the subsequent notification of approval.
Dr. Ernst Heinen, Aratana's Head of Drug Development and Evaluation, will provide an in-depth development update for each of Aratana's current product candidates, each of which is being developed concurrently for both cats and dogs. These include AT-001, the Company's EP4 antagonist for the treatment of pain; AT-002, its ghrelin agonist for treating inappetence; and AT-003, Aratana's liposomal bupivacaine injection for treating post-operative pain.
There will be an opportunity for Q&A after each session, during which Dr. Marie-Paul Lachaud, Aratana's Head of Drug Development in Europe; Tammy Newbold, Aratana's Vice President of Chemistry, Manufacturing and Controls; and Don Stitzenberg, Aratana's Vice President of Manufacturing, will also be available.
About Aratana Therapeutics
Aratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors)
firstname.lastname@example.org; (212) 375-2664
Andrew Mielach (media)
email@example.com; (212) 375-2694
SOURCE Aratana Therapeutics
More by this Source
Aratana Therapeutics to Participate in Upcoming Investor Events
Dec 11, 2013, 16:03 ET
Aratana Therapeutics Adds to Commercial Leadership Team
Oct 24, 2013, 07:30 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.